Immunotherapy Indications Withdrawn In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs? by Anna Goshua New Tactics for Bladder Cancer After decades without treatment advances, options for patients with bladder cancer are now more numerous. by Kendall K. Morgan Survivor Profile Hope and Endurance Bladder cancer survivor Randy Layne and his wife, Ellen, faced his diagnosis, treatment and recovery together. by Martha Irvine Yesterday & Today Who Loves Ya, Baby? Telly Savalas met his match in bladder cancer. Earlier diagnosis and more aggressive treatment might have made a difference. by Jocelyn Selim Cancer Talk Drug Delays Recurrence in People With Early-Stage Breast Cancer People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor. by Pamela Rafalow Grossman Open Medical Records: Pros and Cons Patients now have full access to their online medical records. What are the benefits and downsides? by Jen Tota McGivney Remote Care After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment. by Jon Kelvey Moving Away From the Maximum Tolerated Dose The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate. by Marcus A. Banks More Posts